A Dutch government commission on compulsory licensing was nearly sabotaged last month after one of its members leaked information to a pharmaceutical industry trade group, according to a commission member and a report that was subsequently issued by the head of the committee.

The commission was created last year to research the use of compulsory licenses as a way for the Dutch government to cope with rising prices for prescription medicines. Under world trade rules, a country may grant a license to a public agency or a generic drug maker, allowing it to copy a patented medicine without the consent of the brand-name company that owns the patent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Sorry Ed but I don’t get it. For Covid-19, why can’t the Dutch government simply import remedesivir from India at the dirt cheap price? Per John’s Hopkins dataa from today, we are looking at a mere 51,000 confirmed cases there!

    • Hi John,

      The issue is not anyone drug, of course.
      But to answer your question, the Netherlands would have to be on the list of countries to which the generic manufacturers may sell their versions of the medicine, per the licensing agreement with Gilead.

      Regards
      ed at pharmalot

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy